Hudson Bay Capital Management
DNLI icon

Hudson Bay Capital Management’s Denali Therapeutics DNLI Stock Holding History

Hudson Bay Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.34M Sell
130,000
-216,360
-62% -$4.45M 0.01% 686
2026
Q1 		$6.65M Sell
346,360
-103,640
-23% -$2.06M 0.02% 416
2025
Q4 		$7.43M Buy
450,000
+145,000
+48% +$2.45M 0.02% 396
2025
Q3 		$4.43M Buy
305,000
+15,000
+5% +$216K 0.01% 585
2025
Q2 		$4.06M Buy
290,000
+40,000
+16% +$563K 0.01% 604
2025
Q1 		$3.4M Buy
250,000
+157,500
+170% +$3.02M 0.01% 695
2024
Q4 		$1.89M Buy
92,500
+58,000
+168% +$1.48M 0.01% 671
2024
Q3 		$1M Sell
34,500
-140,500
-80% -$3.48M ﹤0.01% 674
2024
Q2 		$4.06M Sell
175,000
-45,000
-20% -$864K 0.02% 413
2024
Q1 		$4.51M Buy
220,000
+45,000
+26% +$846K 0.03% 321
2023
Q4 		$3.76M Buy
+175,000
New +$3.47M 0.02% 350

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hudson Bay Capital Management's DNLI Position: Q2 2026 in Review

Hudson Bay Capital Management reduced its Denali Therapeutics (DNLI) stake by 62% in Q2 2026, selling an estimated $4.45M and leaving 130,000 shares worth $3.34M. The position accounts for 0.01% of the portfolio, ranked #686.

Hudson Bay Capital Management first reported a position in DNLI in Q4 2023 and has held it in 11 quarters since. The position peaked at $7.43M in Q4 2025. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Hudson Bay Capital Management held 130,000 shares of Denali Therapeutics worth $3.34M as of Q2 2026.
  • Hudson Bay Capital Management sold 216,360 Denali Therapeutics shares in Q2 2026, an estimated $4.45M.
  • Denali Therapeutics made up 0.01% of Hudson Bay Capital Management's portfolio in Q2 2026, its #686 holding.
  • Hudson Bay Capital Management first reported a position in Denali Therapeutics in Q4 2023 and has held it in 11 quarters since.
  • Hudson Bay Capital Management's Denali Therapeutics position peaked at $7.43M in Q4 2025.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.